Yulia Surovtseva
Director 3Cards
About
Research
Publications
2026
Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish
Jamadagni P, Dai Y, Liu Y, Mendes H, Pruitt A, Khan S, Yang L, Huang T, Huang X, Deans P, Balafkan N, Zhao D, Xu G, Liu Y, Li N, Wu W, Fitzpatrick S, Neelakantan U, Chen T, Szialta C, Jin D, Lacadie C, Umlauf S, Papademetris X, Surovtseva Y, Brennand K, Wang Z, Hoffman E. Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2518846123. PMID: 41838920, PMCID: PMC13012064, DOI: 10.1073/pnas.2518846123.Peer-Reviewed Original ResearchConceptsASD genesAutism spectrum disorder genesAutism spectrum disorderBehavioral phenotypesHigh-throughput assayRegional brain activity deficitsGene mutantsUS Food and Drug AdministrationBrain activity deficitsMutantsMetabolic pathwaysFood and Drug AdministrationEstrogen receptor agonistMitochondrial modulatorsGenesReceptor agonistsPhenotypeSignaling deficitsGlutamatergic neuronsSuppressorMicrotubule inhibitorsCarnitine supplementationSpectrum disorderBehavioral profileDrug rescueIn vitro-in vivo discord: A preclinical study of AZD2716 and its racemate with comparison to varespladib for the development of snake venom sPLA2 inhibitors
Hearth J, Surovtseva Y, Karjala Z, Casewell N, Giang K, Lewin M. In vitro-in vivo discord: A preclinical study of AZD2716 and its racemate with comparison to varespladib for the development of snake venom sPLA2 inhibitors. Toxicon X 2026, 29: 100243. PMID: 41737734, PMCID: PMC12926600, DOI: 10.1016/j.toxcx.2026.100243.Peer-Reviewed Original ResearchPreclinical studiesSurvival advantageSPLA2 inhibitorOral drug administrationSingle-doseSurvival durationIV doseClinical developmentMouse modelDrug AdministrationInhibitory profileRescue studiesSurvivalVarespladibDrug candidate selectionInhibition assayInhibitorsSPLA2Snake speciesAssayRacemic mixtureDose
2025
TET3 is a common epigenetic immunomodulator of pathogenic macrophages
Liu B, Dai Y, Wang Z, Song J, Du Y, Lv H, Bellone S, Yang Y, Kennedy A, Zhang S, Venkatachalapathy M, Surovtseva Y, Wang P, Carmichael G, Taylor H, Zhang X, Li D, Huang Y. TET3 is a common epigenetic immunomodulator of pathogenic macrophages. Journal Of Clinical Investigation 2025, 135: e194879. PMID: 40794443, PMCID: PMC12578387, DOI: 10.1172/jci194879.Peer-Reviewed Original ResearchThis study investigates the role of TET3 in promoting pathogenic macrophages across chronic inflammatory diseases, and shows that selectively eliminating TET3-overexpressing macrophages (“Toe-Macs”) can mitigate disease progression in conditions like MASH, NSCLC, and endometriosis.
2024
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, Ahmed M, Umlauf S, Gareiss P, Raaisa R, Williams R, Cardone R, Siebel S, Kibbey R, Surovtseva Y, Pusztai L. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 657-671. PMID: 39177932, DOI: 10.1007/s10549-024-07462-z.Peer-Reviewed Original ResearchMetabolic fluxTriple-negative breast cancerReduced metabolic fluxMDA-MB-231 cellsCell growth in vitroEnzyme assays in vitroMDA-MB-231Potential small molecule inhibitorsPyruvate carboxylaseGrowth in vitroSmall molecule inhibitorsIn silico screeningEnzyme assaysAssay in vitroEnzymatic assayCell lines in vitroEnzyme activityGrowth inhibitory activityBT-549Breast cancerIn vitro screeningBreast cell lines in vitroPhosphoenolpyruvateSignificant growth inhibitory activityLines in vitroThe cytidine deaminase APOBEC3A regulates nucleolar function to promote cell growth and ribosome biogenesis
McCool M, Bryant C, Abriola L, Surovtseva Y, Baserga S. The cytidine deaminase APOBEC3A regulates nucleolar function to promote cell growth and ribosome biogenesis. PLOS Biology 2024, 22: e3002718. PMID: 38976757, PMCID: PMC11257408, DOI: 10.1371/journal.pbio.3002718.Peer-Reviewed Original ResearchRibosome biogenesis factorsRibosome biogenesisBiogenesis factorsCell growthNucleolar functionRegulation of nucleolar functionHuman ribosome biogenesisProtein synthesisProduction of ribosomesFamily of proteinsSource of mutagenesisLevel of protein synthesisCytidine deaminase familyIncreased cell growthPromote cell growthPre-rRNAPotential direct rolePre-mRNATransient overexpressionRibosomeGenomic mutationsBiogenesisMCF10A cellsMaturation stepsAPOBEC3ADiscovery of novel microRNA mimic repressors of ribosome biogenesis
Bryant C, McCool M, González G, Abriola L, Surovtseva Y, Baserga S. Discovery of novel microRNA mimic repressors of ribosome biogenesis. Nucleic Acids Research 2024, 52: 1988-2011. PMID: 38197221, PMCID: PMC10899765, DOI: 10.1093/nar/gkad1235.Peer-Reviewed Original Research
2021
Probing Microbiome Genotoxicity: A Stable Colibactin Provides Insight into Structure–Activity Relationships and Facilitates Mechanism of Action Studies
Wernke KM, Tirla A, Xue M, Surovtseva YV, Menges FS, Herzon SB. Probing Microbiome Genotoxicity: A Stable Colibactin Provides Insight into Structure–Activity Relationships and Facilitates Mechanism of Action Studies. Journal Of The American Chemical Society 2021, 143: 15824-15833. PMID: 34524796, DOI: 10.1021/jacs.1c07559.Peer-Reviewed Original ResearchConceptsFanconi anemia DNA repair pathwayBiosynthetic gene clusterDNA repair pathwaysGene clusterRepair pathwaysDNA bindingBacterial phenotypesInduces DNAGenotoxic effectsHuman microbiomeColibactinBiosynthetic precursorNatural product structuresBiological studiesPathwayStructure-activity relationshipsAction studiesGenotoxic metabolitesOrganismsOncogenesisDNATumorigenesisMicrobiomeFacilitate mechanismsPhenotype
2020
854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy
Yumeen S, Mirza F, Lewis J, King A, Kim S, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy. Journal Of Investigative Dermatology 2020, 140: s111. DOI: 10.1016/j.jid.2020.03.870.Peer-Reviewed Original ResearchScreening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original ResearchJAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibition